ID   MM253
AC   CVCL_2604
SY   MM 253
DR   BioSample; SAMN07624425
DR   cancercelllines; CVCL_2604
DR   CBA; CBA-1347
DR   Cosmic; 889016
DR   Cosmic; 928706
DR   DepMap; ACH-001970
DR   ECACC; 11072804
DR   GEO; GSM78858
DR   GEO; GSM78859
DR   GEO; GSM78860
DR   GEO; GSM162940
DR   GEO; GSM219451
DR   Progenetix; CVCL_2604
DR   Wikidata; Q54906084
RX   PubMed=294576;
RX   PubMed=460945;
RX   PubMed=830403;
RX   PubMed=6187441;
RX   PubMed=7060019;
RX   PubMed=9354451;
RX   PubMed=10070891;
RX   PubMed=15048078;
RX   PubMed=17363583;
RX   PubMed=17516929;
RX   PubMed=22383533;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=17363583).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15048078; PubMed=17363583; PubMed=22383533).
CC   Omics: CNV analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000027.
ST   Source(s): CBA=CBA-1347; DepMap=ACH-001970
ST   Amelogenin: X
ST   CSF1PO: 10,11
ST   D13S317: 11,12
ST   D16S539: 11
ST   D18S51: 18,19
ST   D19S433: 15
ST   D21S11: 29
ST   D2S1338: 16,20
ST   D3S1358: 14
ST   D5S818: 11,12
ST   D7S820: 8,10
ST   D8S1179: 11,14
ST   FGA: 21
ST   Penta D: 12
ST   Penta E: 9,10
ST   TH01: 9.3
ST   TPOX: 8,11
ST   vWA: 16,18
DI   NCIt; C3802; Amelanotic melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   46Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 24
//
RX   PubMed=294576; DOI=10.3109/00313027909059039;
RA   Muir P.D., Gunz F.W.;
RT   "A cytogenetic study of eight human melanoma cell lines.";
RL   Pathology 11:597-606(1979).
//
RX   PubMed=460945; DOI=10.3109/00313027909061945;
RA   Pope J.H., Morrison L.E., Moss D.J., Parsons P.G., Dunne R.M.;
RT   "Human malignant melanoma cell lines.";
RL   Pathology 11:191-195(1979).
//
RX   PubMed=830403;
RA   Goss P.D., Parsons P.G.;
RT   "The effect of hyperthermia and melphalan on survival of human
RT   fibroblast strains and melanoma cell lines.";
RL   Cancer Res. 37:152-156(1977).
//
RX   PubMed=6187441;
RA   Parsons P.G., Musk P., Goss P.D., Leah J.;
RT   "Effects of calcium depletion on human cells in vitro and the
RT   anomalous behavior of the human melanoma cell line MM170.";
RL   Cancer Res. 43:2081-2087(1983).
//
RX   PubMed=7060019;
RA   Parsons P.G., Smellie S.G., Morrison L.E., Hayward I.P.;
RT   "Properties of human melanoma cells resistant to
RT   5-(3',3'-dimethyl-1-triazeno)imidazole-4-carboxamide and other
RT   methylating agents.";
RL   Cancer Res. 42:1454-1461(1982).
//
RX   PubMed=9354451;
RA   Castellano M., Pollock P.M., Walters M.K., Sparrow L.E., Down L.M.,
RA   Gabrielli B.G., Parsons P.G., Hayward N.K.;
RT   "CDKN2A/p16 is inactivated in most melanoma cell lines.";
RL   Cancer Res. 57:4868-4875(1997).
//
RX   PubMed=10070891; DOI=10.1038/sj.bjc.6690147;
RA   Zerp S.F., van Elsas A., Peltenburg L.T.C., Schrier P.I.;
RT   "p53 mutations in human cutaneous melanoma correlate with sun exposure
RT   but are not always involved in melanomagenesis.";
RL   Br. J. Cancer 79:921-926(1999).
//
RX   PubMed=15048078; DOI=10.1038/sj.onc.1207563;
RA   Pavey S., Johansson P., Packer L., Taylor J., Stark M.S., Pollock P.M.,
RA   Walker G.J., Boyle G.M., Harper U., Cozzi S.-J., Hansen K., Yudt L.,
RA   Schmidt C., Hersey P., Ellem K.A.O., O'Rourke M.G.E., Parsons P.G.,
RA   Meltzer P.S., Ringner M., Hayward N.K.;
RT   "Microarray expression profiling in melanoma reveals a BRAF mutation
RT   signature.";
RL   Oncogene 23:4060-4067(2004).
//
RX   PubMed=17363583; DOI=10.1158/0008-5472.CAN-06-4152;
RA   Stark M.S., Hayward N.K.;
RT   "Genome-wide loss of heterozygosity and copy number analysis in
RT   melanoma using high-density single-nucleotide polymorphism arrays.";
RL   Cancer Res. 67:2632-2642(2007).
//
RX   PubMed=17516929; DOI=10.1111/j.1600-0749.2007.00375.x;
RA   Johansson P., Pavey S., Hayward N.K.;
RT   "Confirmation of a BRAF mutation-associated gene expression signature
RT   in melanoma.";
RL   Pigment Cell Res. 20:216-221(2007).
//
RX   PubMed=22383533; DOI=10.1158/1535-7163.MCT-11-0676;
RA   Dutton-Regester K., Irwin D., Hunt P., Aoude L.G., Tembe V.,
RA   Pupo G.M., Lanagan C., Carter C.D., O'Connor L., O'Rourke M.,
RA   Scolyer R.A., Mann G.J., Schmidt C.W., Herington A., Hayward N.K.;
RT   "A high-throughput panel for identifying clinically relevant mutation
RT   profiles in melanoma.";
RL   Mol. Cancer Ther. 11:888-897(2012).
//